Organon & Co. Stock News

Organon & Co (NYSE:OGN ) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Ca

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies

Organon has a solid portfolio driven by steady established brands and fast-growing Women's Health. Management is exercising balance sheet discipline by paying down debt all while maintaining a very we

Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber re

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), a global women's healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the c

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Organon & Co. (NYSE:OGN ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Chris Schott - J

Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.

JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a firesi

Organon & Co. (NYSE:OGN ) Piper Sandler 34th Annual Healthcare Conference November 29, 2022 9:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Con

Organon's third-quarter results show third consecutive quarter of growth, with steady growth across divisions. From inception they have undergone a string of acquisitions and licensing deals that may

Organon & Co. (NYSE:OGN ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Jennifer Halchak – Vice President, Investor Relations Kevin Ali – Chief Executive Office

JERSEY CITY, N.J.

Cramer on Tuesday explained his thoughts on pharmaceutical firm Organon.